Abstract | INTRODUCTION AND OBJECTIVES: METHODS: Male Wistar rats (180-200 g, n=57) randomly received 60 mg/kg monocrotaline or vehicle subcutaneously. Two days later, bosentan was randomly started (300 mg/kg/day) by oral route in a subgroup of monocrotaline-injected rats, while the other monocrotaline-injected and control rats received vehicle. At 25-30 days, invasive hemodynamic assessment was performed under anesthesia, arterial blood samples were collected for gas analysis and plasma was extracted for quantification of endothelin-1, cytokines, nitrates and 6-keto-prostaglandin F1α. Right ventricular myocardium was collected for assessment of cyclooxygenase and nitric oxide synthase activity and gene expression. RESULTS: CONCLUSIONS: In this study we demonstrate that besides attenuating pulmonary hypertension, bosentan has beneficial hemodynamic, myocardial and anti-inflammatory effects.
|
Authors | Dulce Fontoura, José Oliveira-Pinto, Marta Tavares-Silva, Sara Leite, Francisco Vasques-Nóvoa, Pedro Mendes-Ferreira, André P Lourenço, Adelino F Leite-Moreira |
Journal | Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology
(Rev Port Cardiol)
Vol. 33
Issue 4
Pg. 213-22
(Apr 2014)
ISSN: 2174-2030 [Electronic] Portugal |
PMID | 24780128
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2014 Sociedade Portuguesa de Cardiologia. Published by Elsevier España. All rights reserved. |
Chemical References |
- Endothelin Receptor Antagonists
- Sulfonamides
- Monocrotaline
- Bosentan
|
Topics |
- Animals
- Bosentan
- Disease Models, Animal
- Endothelin Receptor Antagonists
(therapeutic use)
- Heart Ventricles
(drug effects)
- Hypertension, Pulmonary
(chemically induced, drug therapy)
- Inflammation
(drug therapy)
- Male
- Monocrotaline
(administration & dosage)
- Rats
- Rats, Wistar
- Sulfonamides
(therapeutic use)
|